Keros Therapeutics Revenue

Biotechnology Research • Lexington, Massachusetts, United States • 101-200 Employees

Keros Therapeutics revenue & valuation

Annual revenue	$232,900,000
Revenue per employee	$2,197,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$745,200,000
Total funding	$196,000,000

Key Contacts at Keros Therapeutics

Joanne Northcutt

Director Head Of Medical Writing

Christine Sproule

Senior Director, Clinical Vendor Management

Raju Nivarthi

Associate Director Of Qc

Joseph Oh

Director Of Quality Operations

Zita Schneider

Associate Director, Corporate Communications

Rosa Grenha

Director, Protein Biochemistry

Bill Aschenbach

Executive Director, Head Of Medical Affairs

Francis Wolenski

Executive Director Of Safety & Bioanalysis

Bob Gay

Senior Director- New Product Planning

Ashley Greeley

Executive Director Of Accounting, Assistant Controller

Company overview

Headquarters	1050 Waltham St, Suite 302, Lexington, Massachusetts 02421, US
Phone number	+16173146297
Website	kerostx.com
NAICS	541714
SIC	283
Founded	2016
Employees	101-200
Socials

Keros Therapeutics Email Formats

Keros Therapeutics uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@kerostx.com), used 75.7% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@kerostx.com	75.7%
{first name}{last name}	johndoe@kerostx.com	19.4%
{first name}	john@kerostx.com	2.9%

About Keros Therapeutics

At Keros, our mission is to innovate therapies that have the potential to shift the treatment paradigm for a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins.

Employees by Management Level

Total employees: 101-200

Seniority

Employees

Director

Senior

Entry

Employees by Department

Keros Therapeutics has 66 employees across 11 departments.

Departments

Number of employees

Funding Data

Explore Keros Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2020-04-04	6	$56,000,000
2024-02-03	14	$140,000,000

Funding Insights

$196,000,000

Total funding amount

$140,000,000

Most recent funding amount

Number of funding rounds

Keros Therapeutics Tech Stack

Discover the technologies and tools that power Keros Therapeutics's digital infrastructure, from frameworks to analytics platforms.

lit-element

JavaScript libraries

Google Maps

Maps

lit-html

JavaScript libraries

MonsterInsights

Analytics

Microsoft 365

Cloudflare

CDN

jQuery Migrate

JavaScript libraries

jQuery

JavaScript libraries

HTTP/3

Miscellaneous

HSTS

Security

PHP

Programming languages

WordPress

Blogs

Frequently asked questions

Keros Therapeutics is located in Lexington, Massachusetts, US.

You can reach Keros Therapeutics at +16173146297.

Keros Therapeutics generates an estimated annual revenue of $232,844,000. This revenue figure reflects the company's market position and business performance in its industry.

Keros Therapeutics has an estimated valuation of $745,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Keros Therapeutics was founded in 2016, making it 10 years old. The company has established itself as a significant player in its industry over this time.

Keros Therapeutics has approximately 101-200 employees. The company continues to grow its workforce to support its business operations and expansion.

Keros Therapeutics has raised a total of $196,000,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.

Key Contacts at Keros Therapeutics

Joanne Northcutt

Director Head Of Medical Writing

Christine Sproule

Senior Director, Clinical Vendor Management

Raju Nivarthi

Associate Director Of Qc

Joseph Oh

Director Of Quality Operations

Zita Schneider

Associate Director, Corporate Communications

Rosa Grenha